Cytek Biosciences, Inc.
CTKB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 14.7% | 10% | -27.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 52.7% | 52.3% | 48.6% | 58.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -8.1% | -7.4% | -19.5% | -4.3% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -10.5% | -12.2% | -27.5% | 16.8% |
| EPS Diluted | -0.04 | -0.044 | -0.09 | 0.073 |
| % Growth | 9.1% | 51.1% | -224% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |